Quantcast

Regulatory properties of copolymer I in Th17 differentiation by altering STAT3 phosphorylation.

Research paper by Chunhua C Chen, Xuebin X Liu, Bing B Wan, Jingwu Z JZ Zhang

Indexed on: 23 Jun '09Published on: 23 Jun '09Published in: Journal of immunology (Baltimore, Md. : 1950)



Abstract

Th17 and Th1 play an important role in multiple sclerosis for which copolymer I (COP-I) is a treatment option. We described here that the treatment effect of COP-I correlated with its unique regulatory properties on differentiation and survival of Th17 in experimental autoimmune encephalomyelitis mice, which was mediated through down-regulation of STAT3 phosphorylation. The effect of COP-I on Th17 differentiation required CD14(+) monocytes through IL-6 signaling as a key mediator to regulate STAT3 phosphorylation and subsequent RORgammat expression in Th17 cells. The observed effect was markedly dampened when monocytes were genetically deficient for IL-6. Similar regulatory properties of COP-I were demonstrated in human Th17 differentiation. The study revealed the differential regulatory roles and the novel mechanism of action of COP-I chiefly responsible for its treatment efficacy in experimental autoimmune encephalomyelitis and multiple sclerosis.